NCT02566759View on ClinicalTrials.gov

A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants

PHASE1TerminatedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

September 23, 2015

Primary Completion Date

June 9, 2016

Study Completion Date

July 12, 2016

Conditions
Schizophrenia, Cerebellar Ataxia
Interventions
DRUG

TAK-831 Oral Suspension

TAK-831 oral suspension.

DRUG

TAK-831 Placebo

TAK-831 placebo-matching oral suspension.

DRUG

TAK-831 Tablet

TAK-831 tablet.

Trial Locations (1)

Unknown

London

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Neurocrine Biosciences

INDUSTRY